inked a co-marketing deal for the screening of GPCR’s and other targets. Evotec will have access to DiscoveRx’ PathHunter
™ and cAMPHunter
™ cell lines as well as EFC chemiluminescent detection technology for use during hit identification and optimization projects performed for Evotec customers.
DiscoveRx’ EFC-related technologies offer assay solutions for every major class of drug target including GPCRs, kinases, proteases, nuclear hormone receptors, and secreted proteins, the company points out. “For our customers this agreement means that DiscoveRx’ innovative assay portfolio of more than 300 cell-based GPCR assays can be accessed in conjunction with the first-class high-throughput screening
set-up at Evotec,” notes Evotec’s evp, business development, Mark Ashton